The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
Quick Searches
Selecting one or more of the options below will update the content below.
- Clinical TrialOntario
What is this Study about?
Participants will receive drug treatment via IV in clinic on Day 1 and every 4 weeks thereafter.
Eligibility Criteria
- Age 50-85 years old
- Diagnosis of early AD
Recruitment End Date
- Clinical TrialOntario
What is this Study about?
Multi-center, Double-Blind, Placebo-Controlled Phase 1/2 Trial to Assess the Safety and Tolerability of WVE-3972-01 Administered Intrathecally to Patients with Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD).
Eligibility Criteria
- 18 Years to 80 Years
- Participants must have a documented mutation (GGGGCC [G4C2] repeat expansion) in the first intronic region of the C9orf72 gene and be diagnosed with ALS or FTD.
- Have a designated study partner
Recruitment End Date
- Clinical TrialOntario
What is this Study about?
A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period.
Eligibility Criteria
- 50 Years to 80 Years
- Diagnosis of prodromal/mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD
- Have a designated study partner
Recruitment End Date
- Clinical TrialBritish Columbia, Nova Scotia, Ontario, Quebec
What is this Study about?
A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE).
Eligibility Criteria
- 55 Years to 85 Years
- MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type
- Have a designated study partner
Recruitment End Date
- Clinical TrialBritish Columbia, Nova Scotia, Ontario, Quebec
What is this Study about?
A Phase 3 randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)
Eligibility Criteria
- 55 Years to 85 Years
- MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type
- Have a designated study partner
Recruitment End Date
- Clinical TrialOntario
What is this Study about?
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
Eligibility Criteria
- 55 Years to 80 Years
- Early Alzheimer's disease (AD)
- Have a designated study partner
Recruitment End Date
- Observational StudyOntario
What is this Study about?
The Health in Aging, Neurodegenerative Diseases and Dementias in Ontario (HANDDS-ONT) Study is an observational study that takes place in the comfort of participant’s home, with no study visits occurring in a clinic. The study is recruiting people living with and without a neurodegenerative disease (see below) or the effects of stroke. Studying both groups will help ONDRI researchers to:
- understand how the diseases affect different people
- discover ways to potentially detect diseases earlier
- explore ways to help people manage their daily health related behaviours
All data collected will be anonymized and will be stored securely by the Ontario Brain Institute.
Eligibility Criteria
- At least 18 years of age
- A resident of Ontario, and
- Must fall under one of the below categories:
- A) Living with a neurodegenerative disease such as:
- Alzheimer’s Disease/Mild Cognitive Impairment
- Parkinson’s Disease
- Amyotrophic Lateral Sclerosis
- Frontotemporal Dementia
- B) Living with the effects of a stroke
Or - C) Living independently with no diagnosis of a neurodegenerative disease
- A) Living with a neurodegenerative disease such as:
Recruitment End Date
- Observational StudyCanada-Wide
What is this Study about?
The Rare Dementia Support Impact Study is a cross-national 5-year collaboration between Nipissing University, Canada; University College London (UCL), England; and Bangor University, Wales, and the world’s largest study on rare dementia support. More than 5% of people living with dementia have a rare or young onset type, which is not well understood.
Eligibility Criteria
- Person living with a rare form of dementia or young onset dementia
- Caregiver for someone with rare or young onset dementia
- 18 years of age or older
- Reside in Canada
Recruitment End Date
- Clinical TrialOntario
What is this Study about?
This is a phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study that will assess efficacy and safety of AL002 administered intravenously (IV) in participants with Early Alzheimer's Disease.
Eligibility Criteria
- 50-85 years old
- Diagnosis of early Alzheimer's Disease
Recruitment End Date
Alzheimer Society of Canada
20 Eglinton Avenue West, 16th Floor
Toronto, Ontario M4R 1K8
Information and Referral Line: 1-855-705-4636
Email: [email protected]
Charity registration number: 11878 4925 RR0001
Follow us: